NVO ▼ -4.8% - Novo Nordisk A/S $NVO Novo Nordisk LLY Eli Lilly: CagriSema Delivers Superior Weight Loss vs. Tirzepatide in REIMAGINE 5 ? • CagriSema patients lost 12.4% of body weight at Week 60 vs. 9.1% with tirzepatide. • Trial used a 1.0 mg dose of each CagriSema component. Novo Nordisk shares fell 4.8% after the company announced that its experimental triple-hormone drug CagriSema delivered superior weight loss compared to Eli Lilly's tirzepatide in the REIMAGINE 5 trial, with CagriSema patients losing 12.4% of body weight versus 9.1% for tirzepatide at Week 60. Despite the positive trial results, the stock decline likely reflects investor concern about increased competitive pressure in the GLP-1 market or questions about CagriSema's regulatory path and commercial viability relative to the already-approved and market-leading tirzepatide. 21-SEP-2026 06:44 AM ET